MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) AND VENOUS THROMBOEMBOLISM (VTE) ACROSS UPADACITINIB CLINICAL TRIAL PROGRAMS IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS

被引：0
|
作者：
Mysler, Eduardo [1 ]
Charles-Schoeman, Christina [2 ]
Choy, Ernest [3 ]
McInnes, Iain [4 ]
Nash, Peter [5 ]
Yamaoka, Kunihiro [6 ]
Lippe, Ralph [7 ]
Khan, Nasser [8 ]
Shmagel, Anna [8 ]
Palac, Hannah [8 ]
Suboticki, Jessica [8 ]
Curtis, Jeffrey [9 ]
机构：
[1] OMI Med Res Org, Buenos Aires, DF, Argentina
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Cardiff Univ, Div Infect & Immun, Cardiff, Wales
[4] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[5] Griffith Univ, Brisbane, Qld, Australia
[6] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[7] AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany
[8] AbbVie, N Chicago, IL USA
[9] Univ Alabama Birmingham, Birmingham, AL USA
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PANLAR2023
引用
收藏
页码：S75 / S76
页数：2
相关论文
共 50 条
  • [41] Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program
    Choy, Ernest
    McInnes, Iain
    Cush, John
    Aelion, Jacob
    Rigby, William
    Song, Yanna
    Meerwein, Sebastian
    Liu, John
    Khan, Nasser
    Suboticki, Jessica
    Cohen, Alexander
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [42] Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    M. Elaine Husni
    Atul Deodhar
    Sergio Schwartzman
    Soumya D. Chakravarty
    Elizabeth C. Hsia
    Jocelyn H. Leu
    Yiying Zhou
    Kim H. Lo
    Arthur Kavanaugh
    Arthritis Research & Therapy, 24
  • [43] Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    Husni, M. Elaine
    Deodhar, Atul
    Schwartzman, Sergio
    Chakravarty, Soumya D.
    Hsia, Elizabeth C.
    Leu, Jocelyn H.
    Zhou, Yiying
    Lo, Kim H.
    Kavanaugh, Arthur
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [44] Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes
    Marotte, Hubert
    Mammar, Nadir
    Fautrel, Bruno
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [45] Co-occurrences of selected cardiovascular diseases and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Han, CL
    Robinson, D
    Hackett, M
    Paramore, C
    Fraeman, K
    Bala, M
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S34 - S35
  • [46] Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
    Hoisnard, Lea
    Vegas, Laura Pina
    Dray-Spira, Rosemary
    Weill, Alain
    Zureik, Mahmoud
    Sbidian, Emilie
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1442 - 1442
  • [47] Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
    Hoisnard, Lea
    Vegas, Laura Pina
    Dray-Spira, Rosemay
    Weill, Alain
    Zureik, Mahmoud
    Sbidian, Emilie
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (02) : 182 - 188
  • [48] IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
    Dougados, M.
    Charles-Schoeman, C.
    Szekanecz, Z.
    Giles, J. T.
    Ytterberg, S. R.
    Bhatt, D. L.
    Koch, G. G.
    Vranic, I.
    Wu, J.
    Wang, C.
    Kwok, K.
    Menon, S.
    Connell, C. A.
    Yndestad, A.
    Rivas, J. L.
    Buch, M. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 175 - 176
  • [49] Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
    Dougados, Maxime
    Charles-Schoeman, Christina
    Szekanecz, Zoltan
    Giles, Jon T.
    Ytterberg, Steven R.
    Bhatt, Deepak L.
    Koch, Gary G.
    Vranic, Ivana
    Wu, Joseph
    Wang, Cunshan
    Kwok, Kenneth
    Menon, Sujatha
    Connell, Carol A.
    Yndestad, Arne
    Rivas, Jose L.
    Buch, Maya H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04) : 575 - 577
  • [50] Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis
    Merjanah, Sali
    Driscoll, Devin
    Peloquin, Christine
    Liew, Jean
    Dubreuil, Maureen
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1471 - 1474
12345